Log in

OTCMKTS:APNHY - ASPEN PHARMACAR/ADR Stock Price, Forecast & News

$5.17
+0.15 (+2.99 %)
(As of 04/1/2020 05:30 AM ET)
Today's Range
$5.17
Now: $5.17
$5.20
50-Day Range
$5.02
MA: $6.48
$7.78
52-Week Range
$4.14
Now: $5.17
$8.73
Volume874 shs
Average Volume2,562 shs
Market Capitalization$2.36 billion
P/E Ratio5.17
Dividend YieldN/A
Beta1.33
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty, branded, and generic pharmaceutical products worldwide. The company offers various oral solid dose, liquids, semi-solids, steriles, biogicals, active pharmaceutical ingredients, and infant nutritional products. It also provides various therapeutic products, including anaesthetics; and injectable anticoagulants comprising orgaran for the treatment of HIT under the Thrombosis brand. In addition, the company offers oncology, endocrinology, and women's health products, as well as consumer healthcare products. Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa.
Read More
ASPEN PHARMACAR/ADR logo

Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:APNHY
Previous SymbolNASDAQ:APNHY
CUSIPN/A
CIKN/A
Phone27-31-580-8600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.74 billion
Cash Flow$1.23 per share
Book Value$8.38 per share

Profitability

Miscellaneous

Employees10,000
Market Cap$2.36 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive APNHY News and Ratings via Email

Sign-up to receive the latest news and ratings for APNHY and its competitors with MarketBeat's FREE daily newsletter.


ASPEN PHARMACAR/ADR (OTCMKTS:APNHY) Frequently Asked Questions

How has ASPEN PHARMACAR/ADR's stock been impacted by COVID-19 (Coronavirus)?

ASPEN PHARMACAR/ADR's stock was trading at $6.75 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, APNHY shares have decreased by 23.4% and is now trading at $5.17. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ASPEN PHARMACAR/ADR?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASPEN PHARMACAR/ADR in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for ASPEN PHARMACAR/ADR.

Has ASPEN PHARMACAR/ADR been receiving favorable news coverage?

Media coverage about APNHY stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ASPEN PHARMACAR/ADR earned a news impact score of -3.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutASPEN PHARMACAR/ADR.

Who are some of ASPEN PHARMACAR/ADR's key competitors?

What other stocks do shareholders of ASPEN PHARMACAR/ADR own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ASPEN PHARMACAR/ADR investors own include LivePerson (LPSN), Alexion Pharmaceuticals (ALXN), DexCom (DXCM), eBay (EBAY), Global Eagle Entertainment (ENT), Gaming and Leisure Properties (GLPI), Kraft Heinz (KHC), Pegasystems (PEGA), Archer Daniels Midland (ADM) and Buckle (BKE).

Who are ASPEN PHARMACAR/ADR's key executives?

ASPEN PHARMACAR/ADR's management team includes the following people:
  • Mr. Stephen Bradley Saad, Group CEO & Exec. Director (Age 55)
  • Mr. Michael Guy Attridge, Deputy Group Chief Exec. & Exec. Director (Age 58)
  • Mr. Sean M. Capazorio, Group Fin. Officer (Age 52)
  • Ms. Lorraine Hill, Group Operating Officer (Age 55)
  • Mr. Riaan Verster BProc, LLM, LLB, ACIS, Company Sec., Group Governance Officer & Group Compliance Officer (Age 43)

What is ASPEN PHARMACAR/ADR's stock symbol?

ASPEN PHARMACAR/ADR trades on the OTCMKTS under the ticker symbol "APNHY."

How do I buy shares of ASPEN PHARMACAR/ADR?

Shares of APNHY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ASPEN PHARMACAR/ADR's stock price today?

One share of APNHY stock can currently be purchased for approximately $5.17.

How big of a company is ASPEN PHARMACAR/ADR?

ASPEN PHARMACAR/ADR has a market capitalization of $2.36 billion and generates $2.74 billion in revenue each year. The company earns $455.64 million in net income (profit) each year or $1.00 on an earnings per share basis. ASPEN PHARMACAR/ADR employs 10,000 workers across the globe. View additional information about ASPEN PHARMACAR/ADR.

What is ASPEN PHARMACAR/ADR's official website?

The official website for ASPEN PHARMACAR/ADR is http://www.aspenpharma.com/.

How can I contact ASPEN PHARMACAR/ADR?

ASPEN PHARMACAR/ADR's mailing address is 9 Rydall Vale Park Douglas Saunders Drive La Lucia Ridge, Durban T3, 4051. The company can be reached via phone at 27-31-580-8600.


MarketBeat Community Rating for ASPEN PHARMACAR/ADR (OTCMKTS APNHY)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  113 (Vote Outperform)
Underperform Votes:  143 (Vote Underperform)
Total Votes:  256
MarketBeat's community ratings are surveys of what our community members think about ASPEN PHARMACAR/ADR and other stocks. Vote "Outperform" if you believe APNHY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APNHY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Featured Article: Quiet Period Expirations

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel